Delphia Therapeutics
Delphia is pioneering activation lethality - a next-generation precision medicine approach that targets cancer's surprising vulnerability to oncogene overactivation.
$67M Series A ·
Led by GV · Source: fundraisingfox.com
Funding history ↓Signals
Website registeredOct 6, 2022 (4 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series A | $67M | fundraisingfox.com |
Timeline
- Website created
Founders and team
KM
Kevin Marks FounderDK
David Kerstein CMORM
Reza Mazhari Chief Business Officer
Investors
Companies like Delphia Therapeutics
LLifeMine Therapeutics$75M Series B+ · Aug 2026
AA2 Biotherapeutics$80M Series B+ · Jan 2025
HHaptena Therapeutics$3.53M Seed · Dec 2025AAccent Therapeutics$75M Series B+ · Jan 2024
HHotSpot Therapeutics$100M Series B+ · Nov 2021
FFrontier MedicinesSeries B+ · Aug 2025
Other companies backed by GV
BBlockaid$40M Series B+ · Nov 2026
LLarridin$30M Series A · Nov 2026
TTamr$21M Series B+ · Oct 2026
BBlacksmith$66M Series B+ · Oct 2026
FFlapping Airplanes$1B Series A · Oct 2026
EEstuary Biotherapeutics$103M Series A · Oct 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/delphia-therapeutics (get a free API key).